Comparative effectiveness research in follicular lymphoma: current and future perspectives and challenges.

about

Disparate survival outcomes after front-line chemoimmunotherapy in older patients with follicular, nodal marginal zone and small lymphocytic lymphoma.Improving the quality of 'personalized medicine' research and practice: through an ethical lens

P2860

Q53039853-1041EB31-F132-4BA9-85CA-F7706B25325F Q56523668-BA372B3C-6AC3-4514-9447-0CBEB15DF22A

P2860

Comparative effectiveness research in follicular lymphoma: current and future perspectives and challenges.

Item

http://www.wikidata.org/entity/Q38171874

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Comparative effectiveness rese ...... e perspectives and challenges.

@en

type

Item

label

Comparative effectiveness rese ...... e perspectives and challenges.

@en

prefLabel

Comparative effectiveness rese ...... e perspectives and challenges.

@en

P1476

Comparative effectiveness rese ...... e perspectives and challenges.

@en

P2093

Kitsada Wudhikarn

http://www.w3.org/2001/XMLSchema#string

P2860

Comparative effectiveness research in oncology

Polymorphisms in DNA repair and one-carbon metabolism genes and overall survival in diffuse large B-cell lymphoma and follicular lymphoma

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects.

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.

Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

P304

95-107

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/CER.13.86

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Brian K Link

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24345259

http://www.w3.org/2001/XMLSchema#string

Comparative effectiveness research in follicular lymphoma: current and future perspectives and challenges.

about

P2860

P2860

Comparative effectiveness research in follicular lymphoma: current and future perspectives and challenges.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698